Hubbry Logo
CoccidioidesCoccidioidesMain
Open search
Coccidioides
Community hub
Coccidioides
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Coccidioides
Coccidioides
Coccidioides
View on Wikipedia
from Wikipedia
Do not confuse Coccidioides (a genus of fungi) with Coccidia (a subclass of protists), nor coccidioidomycosis with coccidiosis.

Coccidioides
Coccidioides immitis
Scientific classification Edit this classification
Kingdom: Fungi
Division: Ascomycota
Class: Eurotiomycetes
Order: Onygenales
Family: Onygenaceae
Genus: Coccidioides
G.W.Stiles (1896)[1]
Type species
Coccidioides immitis
G.W.Stiles (1896)
Species

C. esteriformis
C. histosporocellularis
C. immitis
C. posadasii
C. rosea

Coccidioides is a genus of dimorphic ascomycetes in the family Onygenaceae. Member species are the cause of coccidioidomycosis, also known as San Joaquin Valley fever, an infectious fungal disease largely confined to the Western Hemisphere and endemic in the Southwestern United States.[2] The host acquires the disease by respiratory inhalation of spores disseminated in their natural habitat. The causative agents of coccidioidomycosis are Coccidioides immitis and Coccidioides posadasii. Both C. immitis and C. posadasii are indistinguishable during laboratory testing and commonly referred in literature as Coccidioides.[3]

Clinical presentation

[edit]
C. immitis and C. posadasii share the same asexual life cycle, switching between saprobic (on left) and parasitic (on right) life stages.

Coccidioidomycosis is amazingly diverse in terms of its scope of clinical presentation, as well as clinical severity. About 60% of Coccidioides infections as determined by serologic conversion are asymptomatic. The most common clinical syndrome in the other 40% of infected patients is an acute respiratory illness characterized by fever, cough, and pleuritic pain. Skin manifestations, such as erythema nodosum, are also common with Coccidioides infection. Coccidioides infection can cause a severe and difficult-to-treat meningitis in AIDS and other immunocompromised patients, and occasionally in immunocompetent hosts. Infection can sometimes cause acute respiratory distress syndrome and fatal multilobar pneumonia. The risk of symptomatic infection increases with age.

Epidemiology

[edit]

The primary coccidioidomycosis-endemic areas are located in Southern California and southern Arizona, and northern Mexico, in Sonora, Nuevo León, Coahuila, and Baja California, where it resides in soil.[4] Both C. immitis and C. posadasii were viewed as desert saprophytes, but recent genomic research revealed Coccidioides species to have evolved interacting with their animal hosts.[5]

Etymology

[edit]

The soil fungus Coccidioides was discovered in 1892 by Alejandro Posadas, a medical student, in an Argentinian soldier with widespread disease. Biopsy specimens revealed organisms that resembled the protozoan Coccidia (from the Greek kokkis, "little berry"). In 1896, Gilchrist and Rixford named the organism Coccidioides ("resembling Coccidia") immitis (Latin for “harsh,” describing the clinical course). Ophüls and Moffitt proved that C. immitis was a fungus rather than a protozoan in 1900. In 2002, C. immitis was divided into a second species, C. posadasii, after Alejandro Posadas.[6]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Coccidioides

View on Grokipedia
from Grokipedia
Coccidioides is a of dimorphic ascomycetous fungi consisting of two closely related , Coccidioides immitis and Coccidioides posadasii, that are the causative agents of , a potentially severe respiratory also known as Valley Fever. These soil-dwelling fungi exist in a saprophytic mycelial form in the environment and transform into parasitic spherules within mammalian hosts, with arthroconidia serving as the primary infectious propagules inhaled from airborne dust. Endemic to arid and semiarid regions of the , particularly the , northern Mexico, and parts of Central and , Coccidioides thrive in alkaline soils with high salinity and low , often associated with burrows and disturbed habitats. Incidence has been increasing in recent years, potentially linked to (as of 2025). The two species, phenotypically indistinguishable but differentiated by molecular methods, diverged approximately 5 million years ago, with C. immitis primarily in and C. posadasii distributed more broadly across endemic areas. Genetic studies reveal a genome of approximately 27–29 Mb with evidence of cryptic sexual recombination via mating-type loci. Epidemiologically, coccidioidomycosis affects an estimated 200,000–350,000 people annually , though only about 20,000–25,000 cases are reported (as of 2023), with approximately 60% of infections remaining . Transmission occurs solely through environmental exposure, with no person-to-person spread, and risk factors include dust inhalation during activities like , , or ; incidence is higher among older adults and immunocompromised individuals, where dissemination can occur in less than 5% of cases and prove fatal. Diagnosis relies on , , or , while treatment involves azole antifungals like for mild cases or for severe disseminated disease.

Taxonomy and Phylogeny

Classification

The genus Coccidioides belongs to the kingdom Fungi, phylum , subphylum , class , order Onygenales, and family Onygenaceae. The genus was established in 1896 by Rixford and Gilchrist to describe the causative agent of , initially observed in human tissue samples resembling protozoan . Phylogenetically, Coccidioides is positioned among dimorphic ascomycetes in the Onygenales, sharing close relationships with genera such as Histoplasma and Blastomyces, which also cause systemic mycoses in mammals. This affiliation is supported by molecular analyses of ribosomal (ITS) regions and beta-tubulin genes, which reveal conserved sequences indicative of a common ancestry within the order. The two main pathogenic species in the genus, C. immitis and C. posadasii, diverged approximately 5 million years ago based on genomic analyses. Whole-genome sequencing has illuminated evolutionary adaptations enabling Coccidioides dimorphism and persistence in arid , including contractions in families for plant cell wall degradation (e.g., glycosyl hydrolases) and expansions in animal tissue proteases (e.g., S8 and M35 families), facilitating a shift from saprophytic to parasitic . These changes, alongside conserved regulators like and expansions in FunK1 protein kinases, underpin the thermal dimorphic switch between environmental mycelia and host spherules, while losses in certain transporters (e.g., and ) reflect specialization for host exploitation over broad soil scavenging.

Species

The genus Coccidioides comprises two primary pathogenic : C. immitis, the primarily endemic to , and C. posadasii, which is distributed across the (excluding ) and . These were distinguished based on phylogenetic analyses of single polymorphisms (SNPs), gene sequences, and microsatellites, revealing C. posadasii as a monophyletic, genetically recombining divergent from C. immitis. Comparative genomic studies indicate a sequence identity of 98.3% between the two , corresponding to approximately 1.7% divergence in nonrepetitive regions. Differentiation between C. immitis and C. posadasii relies on (MLST) using 7–8 genes (such as fragments of 450–500 bp) to assess allelic profiles and , as well as (AFLP) analysis to evaluate population structure and low . SNPs in genes serve as key diagnostic markers for identification, enabling precise through phylogenetic clustering and detection of variations that confirm the genetic boundaries between the species. Phenotypic distinctions include slower growth of C. posadasii on high-salt media compared to C. immitis.

Morphology and Life Cycle

Saprobic Phase

The saprobic phase of Coccidioides represents its free-living environmental form, where the grows as mycelia in arid and semi-arid soils, particularly in alkaline desert regions with low organic content. In this stage, it develops extensive networks of septate hyphae that branch and elongate, adapting to nutrient-scarce conditions typical of the , , and parts of Central and . These hyphae mature and fragment asexually into barrel-shaped arthroconidia, the infectious propagules that serve as the primary means of dispersal. Arthroconidia measure approximately 2–4 μm in width and 3–6 μm in length, making them lightweight and easily aerosolized by wind or disturbance. Formation of arthroconidia occurs under favorable conditions, including warm temperatures of 25–30°C and low , which promote hyphal segmentation and release while inhibiting excessive vegetative growth. Reproduction in the saprobic phase is exclusively asexual via arthroconidia production, with no sexual structures observed in natural settings. However, genomic studies have identified mating-type loci (MAT1-1 and MAT1-2) in balanced ratios across isolates, providing genetic evidence for cryptic sexual recombination and potential teleomorphs. Laboratory attempts to induce have been rare and largely unsuccessful, underscoring the predominantly clonal of propagation in the environment.

Parasitic Phase

Upon inhalation into the mammalian respiratory tract, arthroconidia of Coccidioides undergo dimorphic switching to the parasitic phase, developing into large, multinucleate spherules within 8–24 hours. This transformation is triggered primarily by the host's physiological conditions, including a temperature of 37°C and elevated CO₂ levels (10–20%), which mimic the lung environment and induce isotropic growth from the initial arthroconidium. In vivo, these spherules mature to diameters of 30–80 μm, featuring a thick, double-layered cell wall and internal segmentation that partitions the cytoplasm into compartments for endospore formation. As spherules enlarge, they fill with 100–300 endospores, each measuring 2–5 μm in diameter, through successive rounds of endosporulation that begin around 48 hours post-infection. Upon maturation, typically by 96–120 hours, the spherule ruptures, releasing viable endospores into surrounding tissues, which can then differentiate into new spherules and propagate the infection locally or via hematogenous dissemination. This endospore-releasing cycle sustains the parasitic form within the host, though completion of the full life cycle—wherein endospores revert to mycelial growth upon return to soil—is rarely observed in natural settings. In vitro models replicate this parasitic phase by culturing arthroconidia in specialized media, such as Converse medium supplemented with like Tamol SN, at and 10–20% CO₂ to promote spherule development and endosporulation for experimental study. These systems confirm the role of and CO₂ as key environmental cues for dimorphic switching, enabling researchers to dissect the morphological and genetic changes without relying on animal models.

Ecology and Habitat

Environmental Distribution

_Coccidioides species are primarily endemic to arid and semiarid regions of the , with the highest concentrations in the , including California's , , , , and . These fungi also occur in , particularly in the states of and , as well as in parts of Central and , such as . The organism thrives in association with alkaline, sandy soils found in low-altitude desert environments characterized by less than 500 mm of annual rainfall and hot summers. These habitats typically feature sparse xerophytic vegetation and elevated average temperatures, which support the fungus's saprobic growth in the soil. Recent observations indicate an expansion of Coccidioides beyond traditional endemic zones, including detections in non-endemic U.S. states like Washington, attributed to climate change-induced shifts in temperature and precipitation patterns, alongside natural dispersal mechanisms such as wind and human activity. Soil serves as the primary reservoir for Coccidioides, with the identified through environmental sampling techniques that reveal arthroconidia and mycelial forms embedded in soils. Concentrations of viable spores are often highest following rainy seasons, when promotes mycelial proliferation, or during dust storms that aerosolize propagules from disturbed reservoirs.

Growth Conditions

_Coccidioides species thrive in alkaline soils with a range of 7 to 8, which supports mycelial growth and sporulation in their saprobic phase. These fungi exhibit optimal proliferation at temperatures between 25°C and 37°C, aligning with the warm conditions of their endemic arid environments. Low levels, typically below 50% in , further favor their survival by limiting competition from moisture-dependent microbes, while the fungus persists in burrows where accumulation provides a protected, nutrient-rich microhabitat. Nutritionally, Coccidioides is keratinophilic, deriving essential and carbon from in animal remains, as well as decaying vegetation within soil. Growth is inhibited by excessive , which disrupts hyphal development. These constraints underscore the fungus's adaptation to semi-arid conditions with minimal water availability. Sporulation is triggered by environmental cycles of followed by brief rainfall events, promoting initial hyphal growth during wet phases and subsequent arthroconidia fragmentation and aerial dispersal as soils dry. This "grow and blow" dynamic enhances the release of infectious propagules into the air, particularly in dust-prone habitats.00202-9/fulltext)

Pathogenesis

Infection Process

Infection with Coccidioides species typically begins with the of airborne arthroconidia, the infectious propagules measuring 2–5 μm in size, which are released from soil-dwelling mycelia in arid environments. As few as 1–10 arthroconidia are sufficient to initiate in susceptible hosts, with these particles depositing primarily in the terminal bronchioles and alveoli of the lungs following inhalation. Upon deposition, the arthroconidia are rapidly phagocytosed by alveolar macrophages, but the resists killing within these cells, initiating a dimorphic transition triggered by the host's body temperature (37°C) and elevated CO₂ levels (5–10%). This process begins within 8–24 hours post-inhalation, leading to the swelling and remodeling of arthroconidia into immature spherules by 48 hours. Spherule formation continues over the next 48–72 hours, with the structures enlarging to 60–100 μm in by 96–120 hours, during which they evade innate immune responses through their thick, multilayered cell walls that resist further and enzymatic degradation. Inside the maturing spherules, internal septation occurs, culminating in the production of 200–300 endospores (2–4 μm each) that fill the structure. These endospores represent the next propagative phase, allowing the to amplify locally within the pulmonary tissue. The spherules eventually rupture around 120–132 hours, releasing endospores that can infect adjacent cells or be taken up by additional macrophages, perpetuating the cycle and potentially leading to hematogenous or lymphatic dissemination to extrapulmonary sites such as the skin, bones, or in a subset of cases. The dose-response relationship plays a critical role in infection outcomes, where low inocula (1–100 arthroconidia) often result in subclinical or primary infections in approximately 60% of immunocompetent individuals, reflecting effective containment by the host . Higher inoculum exposures, such as those encountered during soil-disturbing activities like or archeological digs, increase the likelihood of symptomatic , though the risk of dissemination remains low (less than 5%) even in these scenarios and is primarily influenced by host factors rather than dose alone.

Virulence Factors

The of Coccidioides , including C. immitis and C. posadasii, relies on several molecular and cellular factors that facilitate host invasion, immune evasion, and survival within the mammalian . These factors enable the to transition from the saprobic arthroconidial phase to the parasitic spherule phase, where it differentiates into large, multinucleate structures that release endospores for . Key among these are surface glycoproteins, enzymes involved in environmental modulation, and antioxidants that counteract host defenses. A prominent is the spherule outer wall (SOWgp), a parasitic-phase-specific adhesin expressed on the surface of maturing spherules. SOWgp binds to host components such as , , and , as well as to type II alveolar cells, promoting fungal attachment and initial colonization of lung tissue. studies demonstrate that disruption of the SOWgp reduces to host cells and attenuates in murine models, with mutants showing decreased fungal burden and prolonged host survival. Additionally, SOWgp contributes to immune evasion by inducing a nonprotective Th2-biased , misdirecting T-cell differentiation away from the protective Th1 pathway and enhancing production against repetitive epitopes that do not confer sterilizing immunity. This immunomodulatory role is supported by the protein's tandem repeats, which evolve through concerted mechanisms like unequal crossing-over, allowing antigenic variation to persist during infection. Urease, encoded by a single in Coccidioides, plays a critical role in by hydrolyzing into and , thereby modulating the of the infection microenvironment and acquiring nutrients. Infected tissues exhibit elevated (up to 7.7), which exacerbates through release, promoting tissue damage and fungal survival in alkaline conditions. Nutrient acquisition is facilitated as the parental strain rapidly consumes exogenous (from 10 mM to 4.2 mM over 7 days ), while -deficient mutants show minimal uptake and reduced production. disruption experiments confirm 's importance, as mutants induce less , form smaller lesions, and yield 55% survival compared to 0% with wild-type strains. This elevation also aids in phagosomal neutralization, enhancing intracellular persistence during early stages. Genomic analyses reveal that Coccidioides genomes, approximately 28-29 Mb in size, encode around 8,000-9,000 protein-coding genes, including a repertoire of secreted effectors that support . Notable among these are chitinases (e.g., CTS2 and CTS3), which are upregulated in the spherule phase and facilitate remodeling during endosporulation and tissue invasion. Disruption of these chitinase genes attenuates fungal replication and , as seen in strains unable to complete . Transcriptomic studies further identify over 40% of putative secreted effectors as proteases, suggesting a strategy for degrading host barriers and evading innate immunity. Resistance to oxidative stress is another essential virulence attribute, mediated primarily by superoxide dismutases (SODs) such as SOD1 and SOD3, which are upregulated during spherule maturation to detoxify reactive oxygen species from host phagocytes. These enzymes enable survival against the oxidative burst in alveolar macrophages, with SOD3's secretion enhancing extracellular protection. Comparative genomics between C. immitis and C. posadasii highlight minor variations in gene content and repetitive elements (e.g., 17% vs. 12% repetitive DNA), but no definitive species-specific differences in virulence potential have been established, though C. posadasii's greater genetic diversity may influence adaptation.

Clinical Manifestations

Primary Infection

Primary infection with Coccidioides species typically occurs following of arthroconidia from in endemic areas, resulting in an initial pulmonary response known as acute or Valley fever. Approximately 60% of infections remain , with no clinical manifestations despite infection. In the remaining 40% of cases that are symptomatic, the ranges from 1 to 3 weeks post-exposure. Symptomatic primary infection presents as a self-limited flu-like illness characterized by fever, dry cough, , , myalgias, and arthralgias. These symptoms generally last 1 to 3 weeks and resolve spontaneously in immunocompetent hosts without specific therapy. Common extrapulmonary signs include or , which appear in 20% to 30% of symptomatic cases as tender, red nodules on the shins or target-like lesions, respectively; these hypersensitivity reactions signal effective and typically resolve without intervention. Chest radiographs in symptomatic patients often show focal or multifocal infiltrates, nodules, or consolidation, predominantly involving the lower lobes, sometimes accompanied by hilar . Serologic testing reveals IgM detection in about 50% of cases within the first week, rising to 70% to 90% by 3 weeks, confirming recent exposure and aiding . In immunocompetent individuals, primary infection rarely progresses beyond the s.

Disseminated Disease

Disseminated coccidioidomycosis occurs when the spreads beyond the primary pulmonary site, affecting extrapulmonary organs and leading to severe, potentially life-threatening complications. This form develops in less than 1% of immunocompetent individuals following primary . In contrast, dissemination affects 30%–50% of immunosuppressed hosts, such as patients with , organ transplants, or those receiving immunosuppressive therapies. The most frequent sites of dissemination are the (in 20%–50% of cases), bones and skin (each in approximately 20%), and chronic pulmonary structures. Meningeal involvement typically manifests as chronic and may progress to due to basilar and adhesions. Skeletal dissemination presents as , often with lytic bone lesions that can cause pain, swelling, and structural damage, particularly in the spine or long bones. Chronic pulmonary involvement includes fibrocavitary disease, leading to persistent cavities and that impair lung function over time. Untreated disseminated disease is usually fatal (mortality approaching 100% in cases involving the ). Certain host factors increase the risk of progression from primary to , including African American or Filipino ethnicity, (particularly in the third trimester), and diabetes mellitus. These risks highlight the importance of monitoring high-risk groups for early signs of spread.

Endemic Areas

Coccidioides species, the fungi responsible for (also known as Valley fever), are primarily endemic to arid and semiarid regions of the , with the core zones concentrated in the and . In the United States, the majority of cases occur in , which accounts for approximately 64.5% of reported infections, followed by with about 32.5%, based on surveillance data from 2011 to 2017. These states, along with smaller foci in , , , and , feature alkaline soils with low where the fungus thrives in undisturbed environments. Emerging endemicity has been observed in previously non-endemic areas due to climate shifts in the 2020s, including increased temperatures and altered precipitation patterns that favor fungal dispersal. In the , cases have surfaced in south-central Washington, linked to local possibly exacerbated by storms and wildfires, while predictive models indicate potential expansion into southern and other northern drylands by mid-century. These changes highlight how warming climates may redistribute Coccidioides beyond traditional boundaries, with initial detections tied to environmental disturbances. Globally, endemic foci extend to scattered regions in , including in and certain areas of , where soil conditions support sporadic outbreaks among human and animal populations. Non-endemic regions like see primarily travel-related imported cases, with reports in 2025 documenting laboratory-confirmed infections in countries such as among individuals returning from endemic zones. These extensions underscore the fungus's adaptation to semi-arid habitats worldwide, though transmission outside the remains rare and importation-driven. A 2025 systematic review identified 39 travel-related and 98 migration-associated infections across from 1948 to 2022. Endemic areas are delineated through comprehensive soil surveys and studies of animal reservoirs, which reveal the fungus's presence in undisturbed soils and its association with burrowing mammals. Surveys across the southwestern U.S. have identified Coccidioides in up to 37% of burrow samples from natural sites, using molecular detection methods to map suitability based on , texture, and moisture. Animals such as coyotes and serve as indicators and potential disseminators, with infection rates in wild populations correlating to high-risk zones and aiding in predictive modeling of exposure areas. , approximately 20,000–23,000 cases of are reported annually to the CDC, primarily from endemic regions in the southwestern states, with 22,939 cases in 2024. This figure represents a substantial increase from earlier decades; for instance, national reported cases rose from around 2,300 in 1998 to over 21,000 by 2023, reflecting an approximately 800% growth driven by factors such as increased construction activities, dust exposure from , and variability that enhances fungal spore dispersal. Provisional data for 2025 indicate continued high incidence, with reporting over 6,700 cases by mid-year and seeing seasonal peaks. In , a key endemic area, case incidence often peaks in late summer and fall following the monsoon season (July–September), when heavy rains promote fungal growth in soil, followed by dry winds that aerosolize arthroconidia. Demographic patterns highlight vulnerable populations, with incidence rates highest among older adults; individuals over 65 years face roughly twice the of severe compared to younger groups, owing to age-related immune decline. Males, particularly those in outdoor occupations like , , and , experience elevated exposure and report higher case rates due to frequent . Ethnic disparities are notable, as people of Filipino ancestry have a 10-fold increased of disseminated relative to , a pattern linked to genetic factors influencing to the . Globally, remains largely confined to the , but imported cases are rising in non-endemic regions like due to international travel and migration. models project further epidemiological shifts, with northward expansion of the fungus's suitable habitat in the U.S. by 2050 under moderate warming scenarios, potentially into states like and , which could amplify incidence through extended arid-dry cycles favoring release.

Diagnosis

Serological Tests

Serological tests for Coccidioides infection primarily detect antibodies produced in response to exposure, aiding in the diagnosis of coccidioidomycosis, particularly in endemic areas where clinical suspicion is high. These assays target immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies, with IgM indicating acute or recent infection and IgG reflecting past or ongoing exposure. Common methods include enzyme immunoassay (EIA) for initial screening and immunodiffusion (ID) for confirmation, often followed by complement fixation (CF) to assess disease severity. Enzyme immunoassay detects IgM and IgG antibodies, with sensitivities ranging from 35% to 61% for IgM and 53% to 69% for IgG in various kits, and specificities of 70% to 100% across commercial assays like those from Meridian Bioscience and IMMY. Immunodiffusion provides higher specificity, exceeding 95%, and is used to confirm positive EIA results by identifying precipitin bands for IgM (early response) or IgG (later response), with overall sensitivity around 60% but greater reliability in non-acute settings. These tests are most effective when performed 1-3 weeks after symptom onset, as IgM antibodies peak during weeks 1-2 and decline after 3-6 months, while IgG rises shortly after and can persist for years, indicating resolved or chronic infection. Complement fixation quantifies IgG levels through serial dilutions, with titers greater than 1:16 often signaling or severe disease, such as extrapulmonary involvement, though titers can remain elevated post-recovery. CF sensitivity ranges from 65% to 83%, with high specificity, but it is less useful early in due to delayed antibody development. False-negative results occur in up to 20-30% of cases, particularly in early before or in immunosuppressed patients who mount weaker immune responses. Antigen detection assays, such as the Coccidioides antigen (EIA) on serum, , or other fluids, provide rapid results and aid , particularly in disseminated or immunocompromised cases. These tests detect fungal antigens with overall sensitivity of approximately 73% and specificity greater than 90%, though sensitivity is higher (up to 90%) in severe disseminated disease and lower (around 50%) in uncomplicated pulmonary cases; with other fungi can occur. Standardization of serological tests is supported by the Centers for Disease Control and Prevention (CDC), which collaborates with reference laboratories and study groups to evaluate commercial assays and reduce interlaboratory variability, ensuring consistent interpretation across clinical settings. Positive in symptomatic patients from endemic regions typically suffices for , though confirmation via may be pursued in ambiguous cases.

Culture and Molecular Methods

Cultivation of Coccidioides species involves inoculating clinical specimens onto standard fungal media such as Sabouraud dextrose or blood , with incubation at 25–30°C yielding initial mycelial colonies in 2–3 days and mature arthroconidia formation within 1–2 weeks. Cycloheximide-supplemented media can be used selectively to inhibit contaminating saprobic fungi while supporting Coccidioides growth. Due to the risk of highly infectious arthroconidia produced in the mycelial phase, all manipulation of sporulating cultures requires biosafety level 3 (BSL-3) facilities and practices to prevent laboratory-acquired infections. , arthroconidia convert to the tissue-invasive spherule phase at mammalian body temperatures (37–40°C), a dimorphic shift that can be replicated in animal models or specialized liquid media like Converse medium for research purposes. Molecular methods for Coccidioides detection primarily utilize (PCR) assays targeting the 1 (ITS1) region of or genus-specific genes such as proline-rich 2 (RRA2), enabling direct identification from clinical specimens like tissue, fluid, or . These assays exhibit high analytical sensitivity, with limits of detection as low as 1 fg of genomic DNA (equivalent to approximately 10 genome copies per reaction), and clinical sensitivities of 80–100% in samples with sufficient fungal burden, outperforming culture in speed and from antifungal-treated patients. Species differentiation between C. immitis and C. posadasii—the two primary pathogens—is achieved via single nucleotide polymorphisms (SNPs) or an 86-bp deletion in targeted amplicons, using probe-based or sequencing approaches integrated into the real-time PCR workflow. Histopathological analysis of tissue biopsies provides direct visualization of Coccidioides spherules, which are large structures (20–80 μm) filled with endospores (2–5 μm), confirming infection through examination of affected organs like , , or , particularly in disseminated cases where spherules are more abundant. These forms are best highlighted by fungal-specific stains such as Gomori methenamine silver (GMS) or periodic acid-Schiff (PAS), which stain the thick double-walled spherule capsules and internal endospores distinctly against surrounding granulomatous inflammation; hematoxylin and eosin (H&E) staining suffices for initial screening but may require silver enhancement for subtle cases. confirmation is particularly valuable in immunocompromised patients with extrapulmonary dissemination, where spherules are more abundant and diagnostic yield is enhanced by targeting suspicious lesions.

Treatment and Management

Pharmacological Therapy

The pharmacological therapy for coccidioidomycosis relies on agents, with azoles serving as first-line treatment for most cases due to their oral and against Coccidioides species. For mild primary pulmonary infections, particularly in patients with symptoms lasting more than a few weeks or those at higher risk such as the elderly or immunocompromised, oral azoles are recommended. at a dose of 400 mg daily or at 200 mg twice daily is typically administered for 3 to 6 months, achieving response rates of 80% to 90% in compliant immunocompetent patients. These regimens promote resolution of symptoms like fever, , and while minimizing dissemination risk. In severe or disseminated disease, including diffuse pneumonia, bone/joint involvement, or meningitis, initial induction therapy involves intravenous lipid formulation of amphotericin B at 3 to 5 mg/kg daily to rapidly control infection, followed by transition to oral azole maintenance. Fluconazole remains the preferred maintenance agent at 400 to 800 mg daily, with durations extending to at least 1 year for non-central nervous system dissemination and lifelong for coccidioidal meningitis to prevent relapse. Itraconazole at 200 mg twice daily serves as an alternative for bone and joint disease, though its absorption requires monitoring. For azole-resistant strains or treatment failures, voriconazole (200 to 400 mg twice daily) is considered an effective alternative, particularly in immunocompromised hosts. Therapeutic monitoring is essential to ensure efficacy and safety, including measurement of serum antifungal drug levels for itraconazole (target trough >1 mcg/mL) and regular assessment of liver function tests due to potential hepatotoxicity. Serial serologic testing, such as complement fixation titers, guides response evaluation, with a decline indicating improvement. Updated 2025 care guidelines emphasize initiating early antifungal therapy in high-risk groups, including those with diabetes, organ transplants, or ethnic predispositions (e.g., African American or Filipino descent), to reduce progression to disseminated forms.

Surgical Interventions

Surgical interventions for coccidioidomycosis are typically reserved for complications that do not respond adequately to antifungal therapy alone, particularly in cases of localized or structural disease involving the , spine, , or lungs. These procedures aim to alleviate symptoms, remove infected tissue, or manage mechanical complications such as effusions, instability, or obstructions. Drainage of is indicated in severe coccidioidal , where accumulation of fluid leads to or hemodynamic compromise. or surgical provides symptomatic relief and facilitates diagnostic sampling, preventing further cardiac compression in affected patients. For vertebral , surgical is recommended when there is spinal instability, cord or compression, or large paraspinal abscesses unresponsive to medical management. Approaches may include anterior, posterior, or lateral access, often combined with stabilization via fusion or to restore structural integrity and reduce neurological deficits. Success rates improve to approximately 86% when surgery is paired with , compared to 58% with antifungals alone. In coccidioidal meningitis complicated by hydrocephalus, ventriculoperitoneal (VP) shunting is the standard intervention for managing increased intracranial pressure and ventriculomegaly due to arachnoid scarring or basal cistern obliteration. This procedure diverts cerebrospinal fluid to prevent progression to coma or death, often requiring multiple revisions, with shunt failure rates of approximately 50% and an average of 2.5 revisions per affected case. Lung resection is considered for chronic fibrocavitary disease, occurring in 5-10% of pulmonary cases, particularly when cavities persist beyond two years, cause , or recur despite treatment. Procedures such as or segmentectomy, often via (VATS), achieve success rates of 70-85% when combined with adjunct antifungals, with low recurrence in experienced centers. These interventions complement the primary backbone by addressing persistent structural lesions. Emerging minimally invasive techniques, such as CT-guided or aspiration, are increasingly used for diagnostic confirmation and targeted drainage in accessible lesions like vertebral abscesses or pulmonary nodules, reducing the need for open . Postoperative recurrence rates following these approaches hover around 20%, emphasizing the importance of long-term follow-up to mitigate .

Prevention and Control

Environmental Measures

Environmental measures for controlling Coccidioides exposure focus on mitigating the dispersal of fungal spores from in endemic areas, primarily through suppression and regulatory oversight. In and land disturbance activities, remediation strategies include wetting the ground with trucks to prevent airborne particles, covering piles with tarps, and applying stabilizers or promoting growth to stabilize surfaces. These approaches have been recommended following outbreaks linked to site development, such as solar farm projects where inadequate control led to increased cases among workers. Surveillance efforts are essential for early detection and response, with coccidioidomycosis designated as a nationally by the CDC, requiring reporting of cases to track incidence and guide interventions. Environmental sampling, particularly air monitoring after dust storms, helps identify spore presence; for instance, studies in , have detected Coccidioides DNA in air filters collected post-storm, informing alerts. While rodents serve as natural hosts that may disturb soil and release spores from burrows, targeted remains limited due to challenges in detecting infected animals. U.S. policy frameworks emphasize risk reduction in high-risk activities like and through guidelines from agencies such as OSHA and the USGS. These include mandatory dust control plans for fieldwork in endemic zones, such as limiting ground disturbance and using stabilizers during excavations. The CDC highlights as an occupational risk factor and promotes site-specific measures to curb exposure in arid regions.

Personal Protective Strategies

Individuals engaging in outdoor activities in endemic areas for Coccidioides, such as , excavation, or , should prioritize avoiding dust exposure to minimize of infectious arthroconidia. In dusty conditions, particularly during dry seasons when winds disperse particles, refraining from soil-disturbing tasks like digging is advised, as these periods heighten aerosolization risks. If avoidance is not feasible, wearing a properly fitted is recommended to filter airborne particles effectively, reducing exposure in high-dust environments like construction sites. For high-risk populations, including pregnant individuals and those who are immunocompromised (e.g., due to , , or use), stricter precautions are essential given their elevated likelihood of severe or disseminated . These groups should consult healthcare providers about avoiding non-essential to hotspots in the and limiting participation in soil-disrupting activities altogether. In cases of known exposure, such as laboratory accidents involving Coccidioides cultures, with oral azoles like (400 mg daily) or (200 mg twice daily) for 6 weeks may be considered for non-pregnant, exposed individuals to prevent primary , though evidence is limited and decisions should involve infectious specialists. Immediate , such as washing skin with soap and water, is also advised following potential contact. Public education plays a key role in personal prevention, with awareness campaigns in promoting recognition of risks and adoption of protective behaviors among residents and workers. These initiatives, supported by state health departments and centers like the Valley Fever Center for Excellence, have enhanced community knowledge and encouraged proactive measures to curb infections.

Vaccine Development

No licensed exists for as of November 2025, but research has advanced a live attenuated candidate toward Phase 1 clinical trials, supported by the . This development aims to provide long-term protection for at-risk populations in endemic regions, building on preclinical studies demonstrating efficacy in animal models.

History

Discovery and Early Research

The first description of what is now known as occurred in 1892, when Argentine medical student Alejandro Posadas and Roberto Wernicke observed skin lesions in a 32-year-old in , initially mistaking the causative agent for a protozoan resembling due to the observed spherule-like structures in tissue samples. Posadas's and Wernicke's case report marked the initial recognition of the disease, though its fungal remained unrecognized at the time. In 1896, American physicians Thomas Caspar Gilchrist and Emmet Rixford reported a similar case in a farm worker in San Francisco, California, naming the organism Coccidioides immitis based on its resemblance to coccidian protozoa and the severe clinical course observed. This naming stemmed from a U.S. patient with disseminated lesions, providing the first detailed pathological description outside Argentina. Four years later, in 1900, William Ophüls and Herbert C. Moffitt at Cooper Medical College (now Stanford) confirmed the fungal nature of C. immitis by successfully culturing the organism from a patient's lung tissue, revealing its dimorphic characteristics with a mold phase in vitro and spherules in vivo. Their work, including animal inoculation experiments, definitively shifted classification from protozoan to fungus and highlighted the pulmonary primary site of infection. During the mid-20th century, particularly from the 1930s to 1950s, researchers elucidated the full life cycle of Coccidioides, establishing its dimorphic nature and environmental reservoir. In 1932, R. A. Stewart and Kenneth F. Meyer isolated the fungus from soil samples, linking it directly to environmental exposure through guinea pig inoculations and demonstrating its saprobic growth in alkaline desert soils. Building on this, Charles E. Smith and colleagues at conducted extensive field studies in the 1940s, identifying arthroconidia as the airborne infectious propagules produced in the mycelial soil phase, which transform into tissue spherules upon inhalation, thus completing the cycle from saprophyte to parasite. These findings, driven by increased cases during Dust Bowl migrations and military training in endemic areas, provided critical insights into transmission dynamics. A major taxonomic advancement came in 2002, when Matthew C. Fisher and colleagues used multilocus to distinguish a second species, Coccidioides posadasii, from C. immitis, based on genetic divergence among non-California isolates from , , and . This split, supported by phenotypic differences like slower growth on high-salt media, honored Posadas's original discovery and clarified geographic without altering the shared life cycle or clinical presentation.

Etymology

The genus name Coccidioides derives from the Greek words kokkis (κόκκος), meaning "berry" or "little berry," and eidos (εἶδος), meaning "form" or "resemblance," reflecting the spherical, berry-like appearance of the organism's spherules that initially resembled those of the protozoan group . This nomenclature was coined in 1896 by American physicians T. Caspar Gilchrist and Emmet Rixford, who classified the pathogen among the Sporozoa based on its morphological similarity to coccidian parasites. The species epithet immitis comes from the Latin word meaning "harsh" or "unyielding," chosen to describe the severe and aggressive clinical course of the disease it causes. In contrast, Coccidioides posadasii was formally described as a distinct species in 2002, with its epithet honoring Alejandro Posadas, the Argentine medical student who first reported a case of in 1892 and contributed to its early recognition. This taxonomic split distinguished non-California populations from C. immitis, which is primarily associated with California's . The early nomenclature of Coccidioides was heavily influenced by initial misclassification as a coccidian parasite, stemming from the discovery of large, double-contoured spherules in tissue samples that mimicked protozoan structures, leading researchers like Gilchrist to place it within the Sporozoa subclass before its fungal nature was confirmed in the early 1900s. This confusion delayed accurate identification but underscored the pathogen's unique dimorphic life cycle, which alternates between tissue spherules and environmental mycelia.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK448161/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6527015/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC9409882/
  4. https://www.cdph.ca.gov/Programs/OPA/Pages/NR25-010.aspx
  5. https://journals.asm.org/doi/10.1128/mbio.00550-16
  6. https://www.cdc.gov/valley-fever/php/statistics/index.html
  7. https://beaconbio.org/en/event/?eventid=8d20a899-582e-430b-b83d-df6a58e14b38
  8. https://www.mycobank.org/details/708/5802
  9. https://acir.aphis.usda.gov/s/cird-taxon/a0ut0000002IbLZAA0/coccidioides-immitis
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3702223/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC6879716/
  12. https://www.nature.com/articles/s41598-018-22816-6
  13. https://www.tandfonline.com/doi/full/10.1080/15572536.2003.11833250
  14. https://www.elsevier.es/en-revista-revista-iberoamericana-micologia-290-articulo-molecular-markers-in-epidemiology-diagnosis-S1130140613001058
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC8340492/
  16. https://www.cfsph.iastate.edu/Factsheets/pdfs/coccidioidomycosis.pdf
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC6927309/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3719491/
  19. https://taylorlab.berkeley.edu/sites/default/files/taylorlab/publications/matute2006b.pdf
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC7271979/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC1828958/
  22. https://www.cdc.gov/valley-fever/areas/index.html
  23. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1902-7
  24. https://agupubs.onlinelibrary.wiley.com/doi/full/10.1029/2019GH000209
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC10128028/
  26. https://www.mdpi.com/2076-3298/12/8/258
  27. https://nyaspubs.onlinelibrary.wiley.com/doi/10.1196/annals.1406.031
  28. https://escholarship.org/content/qt12k8s3tg/qt12k8s3tg.pdf
  29. https://agupubs.onlinelibrary.wiley.com/doi/full/10.1002/2016GH000033
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC10189771/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC8887663/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC128074/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC1456504/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC1346605/
  35. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006149
  36. https://www.kegg.jp/kegg-bin/show_organism?org=cpw
  37. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.00483/full
  38. https://journals.asm.org/doi/10.1128/iai.00459-09
  39. https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003066
  40. https://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-13-121
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2765278/
  42. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5805a1.htm
  43. https://odh.ohio.gov/know-our-programs/infectious-disease-control-manual/section3/section-3-coccidioidomycosis
  44. https://www.sandiegocounty.gov/content/sdc/hhsa/programs/phs/community_epidemiology/dc/Coccidioidomycosis.html
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4631225/
  46. https://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/valley-fever/cocci-clinician-guide.pdf
  47. https://emedicine.medscape.com/article/215978-workup
  48. https://publications.aap.org/redbook/book/755/chapter/14076385/Coccidioidomycosis
  49. https://wwwnc.cdc.gov/eid/article/23/2/16-0505_article
  50. https://www.sciencedirect.com/science/article/pii/S1930043316301017
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC10607509/
  52. https://health.ucdavis.edu/valley-fever/about-valley-fever/clinical-manifestations/coccidioidal-meningitis/index.html
  53. https://emedicine.medscape.com/article/2137779-overview
  54. https://www.thoracic.org/patients/patient-resources/resources/coccidioidomycosis.pdf
  55. https://www.merckmanuals.com/professional/infectious-diseases/fungi/coccidioidomycosis
  56. https://www.uptodate.com/contents/coccidioidal-meningitis
  57. https://health.ucdavis.edu/conditions/valley-fever
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC6756189/
  59. https://www.mdpi.com/2075-1729/13/11/2109
  60. https://journals.asm.org/doi/10.1128/mbio.00232-23
  61. https://pipd.ncipd.org/index.php/pipd/article/view/53-2-8-rare-case-of-coccidioidomycosis
  62. https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaf407/8315808?searchresult=1
  63. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247263
  64. https://www.osti.gov/biblio/1984102
  65. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021009
  66. https://academic.oup.com/mmy/article/57/Supplement_1/S30/5300140
  67. https://www.cdc.gov/valley-fever/hcp/clinical-overview/index.html
  68. https://emedicine.medscape.com/article/215978-overview
  69. https://www.sciencedirect.com/science/article/pii/S0160412024006524
  70. https://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/investigation-manual/other/coccidioidomycosis.pdf
  71. https://www.cdc.gov/valley-fever/media/pdfs/2024/05/333421-B_FS_CocciAlgorithm_V7-1.pdf
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC10204634/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC6258849/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC2780641/
  75. https://www.uptodate.com/contents/coccidioidomycosis-laboratory-diagnosis-and-screening
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC8835625/
  77. https://journals.asm.org/doi/10.1128/jcm.01581-22
  78. https://www.sciencedirect.com/science/article/abs/pii/S0732889314000625
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC8486383/
  80. https://www.idsociety.org/practice-guideline/coccidioidomycosis/
  81. https://cchcs.ca.gov/wp-content/uploads/sites/60/Coccidioidomycosis_Care_Guide.pdf
  82. https://www.cdc.gov/valley-fever/treatment/index.html
  83. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/coccidioidomycosis
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC11908537/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC11443987/
  86. https://www.sciencedirect.com/science/article/pii/S2211753923000477
  87. https://thejns.org/view/journals/j-neurosurg/121/4/article-p785.xml
  88. https://www.annalsthoracicsurgery.org/article/S0003-4975%2809%2901579-3/fulltext
  89. https://journal.chestnet.org/article/S0012-3692%2824%2905614-9/fulltext
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC5903411/
  91. https://emedicine.medscape.com/article/215978-treatment
  92. http://www.osha.gov/valley-fever/control-prevention
  93. https://www.ehs.ucsb.edu/programs-services/industrial-hygiene/valley-fever
  94. https://www.cdc.gov/mmwr/volumes/67/wr/mm6733a4.htm
  95. https://www.cdc.gov/mmwr/volumes/71/ss/ss7107a1.htm
  96. https://academic.oup.com/mmy/article/58/4/552/5567250
  97. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011391
  98. https://www.mdpi.com/2309-608X/10/10/724
  99. https://pubs.usgs.gov/publication/ofr00348
  100. https://www.cdc.gov/valley-fever/prevention/index.html
  101. https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/ValleyFeverPrevention.aspx
  102. https://www.cdc.gov/mmwr/preview/mmwrhtml/00038328.htm
  103. https://academic.oup.com/cid/article/49/6/919/334683
  104. https://pubmed.ncbi.nlm.nih.gov/19663562/
  105. https://vfce.arizona.edu/
  106. https://www.jsr.org/hs/index.php/path/article/view/7585
  107. https://healthsciences.arizona.edu/news/stories/pursuit-valley-fever-vaccine-passes-significant-milestone
  108. https://www.niaid.nih.gov/sites/default/files/valley-fever-strategic-plan-final-updated-march-2025.pdf
  109. https://academic.oup.com/cid/article/44/9/1202/328906
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC4451898/
  111. https://jamanetwork.com/journals/jama/fullarticle/453718
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC6347077/
  113. https://journals.sagepub.com/doi/abs/10.3181/00379727-29-6159
  114. https://www.tandfonline.com/doi/abs/10.1080/15572536.2003.11833250
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC6347081/
  116. https://www.tandfonline.com/doi/full/10.2147/CLEP.S34434
Add your contribution
Related Hubs
User Avatar
No comments yet.